Texas jury awards Seagen nearly $42M in Enhertu patent case
AstraZeneca and Daiichi Sankyo put a lot on the line to position Enhertu as the next big breast cancer drug, one that analysts say could …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
